NCT07230353RecruitingPhase 1
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 1 Oct 2025
- Start date
- Oct 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Xencor, Inc.
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07230353
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 68
- From Oct 2025 to the primary completion date, Jun 2028
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
Other illness
- Recurrent infections or active clinically significant infection
- Active or untreated latent tuberculosis
- Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
- Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
- Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.
Who the study is looking for
- Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
- Inadequate response to, loss of response to, or intolerance to available RA therapies.
- Stable doses of RA medications prior to screening
- Use of highly effective methods of contraception
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Tbilisi | Georgia | Recruiting |
| - Coordinator of this site? Confirm its status | Chisinau | Moldova | Recruiting |
| - Coordinator of this site? Confirm its status | Auckland | New Zealand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.